As of 2026-09-06, the Relative Valuation of CytomX Therapeutics Inc (CTMX) is (7.74) USD. This relative valuation is based on P/E multiples. With the latest stock price at 3.71 USD, the upside of CytomX Therapeutics Inc based on Relative Valuation is -308.6%.
The range of the Relative Valuation is (6.12) - (8.12) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 16.7x - 22.2x | 20.5x |
| Forward P/E multiples | 14.9x - 27.5x | 21.8x |
| Fair Price | (6.12) - (8.12) | (7.74) |
| Upside | -265.1% - -318.9% | -308.6% |
| Date | P/E |
| 2026-09-04 | -10.14 |
| 2026-09-03 | -10.06 |
| 2026-09-02 | -10.17 |
| 2026-09-01 | -10.03 |
| 2026-08-31 | -9.18 |
| 2026-08-28 | -8.77 |
| 2026-08-27 | -9.35 |
| 2026-08-26 | -9.07 |
| 2026-08-25 | -9.21 |
| 2026-08-24 | -8.99 |
| 2026-08-21 | -8.96 |
| 2026-08-20 | -8.99 |
| 2026-08-19 | -9.76 |
| 2026-08-18 | -9.27 |
| 2026-08-17 | -9.43 |
| 2026-08-14 | -9.18 |
| 2026-08-13 | -9.16 |
| 2026-08-12 | -9.54 |
| 2026-08-11 | -9.43 |
| 2026-08-10 | -9.40 |
| 2026-08-07 | -9.46 |
| 2026-08-06 | -9.21 |
| 2026-08-05 | -9.16 |
| 2026-08-04 | -9.07 |
| 2026-08-03 | -8.66 |
| 2026-07-31 | -8.47 |
| 2026-07-30 | -8.96 |
| 2026-07-29 | -8.66 |
| 2026-07-28 | -8.80 |
| 2026-07-27 | -8.88 |
| 2026-07-24 | -8.86 |
| 2026-07-23 | -9.10 |
| 2026-07-22 | -9.10 |
| 2026-07-21 | -9.35 |
| 2026-07-20 | -9.62 |
| 2026-07-17 | -9.89 |
| 2026-07-16 | -10.02 |
| 2026-07-15 | -10.06 |
| 2026-07-14 | -10.00 |
| 2026-07-13 | -10.11 |
| 2026-07-10 | -10.28 |
| 2026-07-09 | -10.81 |
| 2026-07-08 | -10.47 |
| 2026-07-07 | -10.50 |
| 2026-07-06 | -10.41 |
| 2026-07-02 | -10.44 |
| 2026-07-01 | -9.84 |
| 2026-06-30 | -10.25 |
| 2026-06-29 | -10.22 |
| 2026-06-26 | -9.29 |